SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-220559
Filing Date
2022-08-15
Accepted
2022-08-15 07:22:03
Documents
14
Period of Report
2022-08-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d347000d8k.htm   iXBRL 8-K 25687
2 EX-99.1 d347000dex991.htm EX-99.1 77971
6 GRAPHIC g347000g12x56.jpg GRAPHIC 9842
  Complete submission text file 0001193125-22-220559.txt   252515

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA adgi-20220815.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE adgi-20220815_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE adgi-20220815_pre.xml EX-101.PRE 11702
8 EXTRACTED XBRL INSTANCE DOCUMENT d347000d8k_htm.xml XML 3469
Mailing Address 1601 TRAPELO ROAD SUITE 178 WALTHAM MA 02451
Business Address 1601 TRAPELO ROAD SUITE 178 WALTHAM MA 02451 (781) 819-0080
Adagio Therapeutics, Inc. (Filer) CIK: 0001832038 (see all company filings)

IRS No.: 851403134 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40703 | Film No.: 221162314
SIC: 2836 Biological Products, (No Diagnostic Substances)